Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TGF-β Inhibitor Potentiates Osimertinib-Induced Anti-Tumor Immunity in Egfr-Mutant Lung Cancer.

Cancer science - 1 May 2026

Kuribayashi Tadahiro, Nishimura Jun, Okawa Sachi, Taoka Masataka, Mori Shunta, Tanaka Takaaki, Nishimura Tomoka, Morita Ayako, Hara Naofumi, Ninomiya Kiichiro, Makimoto Go, Rai Kammei, Ichihara Eiki, Hotta Katsuyuki, Togashi Yosuke, Maeda Yoshinobu, Kiura Katsuyuki, Ohashi Kadoaki

Abstract excerpt

Immunotherapy for epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) remains challenging. We previously found that EGFR-tyrosine kinase inhibitors induced antitumor immunity but also triggered immunosuppressive cytokines, including transforming growth factor-β (TGF-β), in Egfr-mutant lung cancer. Here, we investigate whether TGF-β inhibition potentiates osimertinib-induced...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to Indoles

Share to Protein Kinase Inhibitors

Share to Pyrimidines

Share to Transforming Growth Factor beta

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 41757675
DOI: 10.1111/cas.70352
PMCID: PMC13134516

Genes

EGFR
CD44
SMAD2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TGF-β Inhibitor Potentiates Osimertinib-Induced Anti-Tumor Immunity in Egfr-Mutant Lung Cancer.PMID 41757675Read ↗

EGFR mutations induce the suppression of CD8+ T cell and anti-PD-1 resistance via ERK1/2-p90RSK-TGF-β axis in non-small cell lung cancer.Semantic proximity Read ↗

Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer.Semantic proximity Read ↗

IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC.Semantic proximity Read ↗

<p>Immunotherapy after EGFR‑TKI treatment in advanced non‑small cell lung cancer: Current status and future perspectives (Review)</p>.Semantic proximity Read ↗

Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response.Semantic proximity Read ↗

Perioperative immunotherapy for patients with EGFR mutant non-small cell lung cancer: Unexpected potential benefits.Semantic proximity Read ↗

Osimertinib Plus Durvalumab in Patients With EGFR-Mutated, Advanced NSCLC: A Phase 1b, Open-Label, Multicenter Trial.Semantic proximity Read ↗

Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer.Semantic proximity Read ↗

Immunological effects of amivantamab in EGFR or MET-expressing non-small cell lung cancerSemantic proximity Read ↗

CD8+ T-cell Responses Are Boosted by Dual PD-1/VEGFR2 Blockade after EGFR Inhibition in Egfr-Mutant Lung Cancer.Semantic proximity Read ↗

Interleukin-1α-Mediated Activation of TNF-α/NF-κB Signaling Confers Resistance to Osimertinib in EGFR-Mutant Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.